ASH 2016: What To Watch in San Diego

Share this content:
Next week, researchers will meet in San Diego, California, at the American Society of Hematology (ASH) 58th Annual Meeting & Exposition.
Next week, researchers will meet in San Diego, California, at the American Society of Hematology (ASH) 58th Annual Meeting & Exposition.

Next week, researchers will meet in San Diego, California, at the American Society of Hematology (ASH) 58th Annual Meeting & Exposition to present data from hundreds of studies conducted for patients with hematologic malignancies and blood disorders.

Topics of interest at this year's ASH annual meeting include: phase 3 trials for lymphoma and other hematologic cancers, gene therapy/immunotherapy, stem cells, and sickle cell disease.

Clinicians should watch for the following 3 randomized phase 3 trials in patients with lymphoma, all of which met their primary endpoints:

  • Abstract 613: Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study ( Identifier: NCT01332968)
  • Abstract 182: Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous t cell lymphoma versus physician's choice (methotrexate or bexarotene): The phase 3 Alcanza study ( Identifier: NCT01578499)
  • Abstract 145: Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: Final results of the randomized phase 3 LyMa trial of the Lysa/Goelams Group ( Identifier: NCT00921414

Noteworthy phase 3 studies in patients with other hematologic malignancies include:

  • Abstract 229: Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: Interim results of a phase 3 study (CLL M1 study of the German CLL Study Group) ( Identifier: NCT01556776)
  • Late-breaking abstract 5: Results of the PERSIST-2 phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in patients with myelofibrosis (MF) and platelet counts less than 100,000/µL ( Identifier: NCT02055781)
  • Late-breaking abstract 1: Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (len) and dexamethasone (RVD) consolidation with len maintenance (ACM), tandem autoHCT with len maintenance (TAM) and autoHCT with len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): Primary results from the randomized Phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial) ( Identifier: NCT01109004)

Two additional studies related to immunotherapy to be presented at the ASH meeting that may inform clinical practice are:

  • Abstract 650: Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) ( Identifier: NCT02315612)
  • Late-breaking abstract 6: Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): Results from the pivotal phase 2 ZUMA-1 ( Identifier: NCT02348216)


  1. Papers to be presented at: American Society of Hematology (ASH) 58th Annual Meeting & Exposition; December 3-6, 2016; San Diego, CA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs